Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 11/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977574 | 0.93 | SLC7A5 (0.54) | SLC7A5PPARGPPARAPPARDMEN1 | |
| SCHEMBL6818678 | 0.90 | PPARG (0.46) | SLC7A5PPARGSMN1; SMN2PPARAPPARD | |
| SCHEMBL978773 | 0.90 | SLC7A5 (0.62) | SLC7A5PPARGPPARAPPARD | |
| SCHEMBL3541115 | 0.81 | MMP8 (0.56) | PPARGPPARAPPARDMMP8 | |
| SCHEMBL27546630 | 0.81 | MMP8 (0.56) | PPARGPPARAPPARDMMP8 | |
| SCHEMBL978598 | 0.81 | PPARG (0.48) | PPARGPPARAPPARD | |
| SCHEMBL978301 | 0.80 | ESR1 (0.46) | PPARGPPARAPPARD | |
| SCHEMBL6818879 | 0.80 | PPARG (0.43) | SLC7A5PPARGSMN1; SMN2PPARAPPARD | |
| SCHEMBL6834707 | 0.80 | PPARG (0.56) | SLC7A5PPARGPPARAPPARD | |
| SCHEMBL3374631 | 0.78 | PPARA (0.41) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | disclosed |
| EP-2125711-B1 | 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008108735-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| US-6750252-B2 | FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1237856-B1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | TPMT, FABP2, PTGES2 | SLC7A5 1431/4885PPARG 35/4885SMN1; SMN2 2740/4885 |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | SLC7A5 1124/4885PPARG 25/4885SMN1; SMN2 2799/4885 |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | SLC7A5 1124/4885PPARG 25/4885SMN1; SMN2 2799/4885 |
| US-20030149104-A1 | Tri-substituted phenyl derivatives and analogues | GPR119, IAPP, INSR | SLC7A5 1318/4885PPARG 46/4885SMN1; SMN2 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.